Share your interactive ePaper on all platforms and on your website with our embed function. C: Tablet of 0. Dispersible tablet with 0. D: Certican should only be prescribed by physicians who are experienced in immunosuppressive therapy.
Adults: Initial dose regimen of 0. Routine blood level monitoring. CI: Hypersensitivity to everolimus, sirolimus or one of the excipients. Antimicrobiological prophylaxis for Pneumocystis jiroveci carinii pneumonia for the first 12 months following transplantation, CMV prophylaxis for 3 months after transplantation. Elevated serum creatinine levels: ciclosporin dose reduction should be considered. Rare hereditary problems of lactose intolerance, lactase deficiency or glucose-galactose malabsorbtion.
Breast feed not recommended. UE: Very common: leucopenia, hypercholesterolemia, hyperlipidemia. Common: viral, bacterial or fungal infections, sepsis. Lymphoma, lymphoproliferative disease. Hypertension, lymphocele in renal transplantation , venous thromboembolism. Acne, surgical wound complication. Urinary tract infection.
Bioavailability of everolimus increased by co-administration of ciclosporin: dose adjustments for both medicinal products. Vaccination; avoid live vaccines. P: Tablets of 0. Dispersible tablets of 0. Sale category: B. For further information, please consult the Swiss Compendium of Drugs. References: 1. Eisen HJ et al. N Engl J Med ; Tedesco-Silva H et al. Transplant Int ; Vitko S et al. Transplantation ; 78 10 : Pascual J. Concentration-controlled everolimus Certican : combination with reduced dose calcineurin inhibitors.
Transplantation ; 79 3S : SS Wang SS et al. Cyclosporine reduction in the presence of concentration-controlled everolimus in de novo cardiac transplantation: 6-month study results. Transplant Int ; 20 2S : 94, abstract O Die Videoinstallation wird im Foyer 2. Here in Basel, strange characters have developed.
